C4 Therapeutics Inc (CCCC)

$3.56 +0.04 (1.14%)
Market Cap 393.62M
Revenue (ttm) 35.95M
Net Income (ttm) -104.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -292.04%
Debt to Equity Ratio 0.00
Volume 1,707,800
Avg Vol 2,805,682
Day's Range N/A - N/A
Shares Out 110.57M
Stochastic %K 57%
Beta 2.77
Analysts Strong Sell
Price Target $11.57

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
JuggernautRaider
JuggernautRaider May. 23 at 5:40 PM
$TNXP in touch with a former tonix employee right now gathering info… my private server will also feature competitive intelligence you won’t get anywhere on TNXP and other companies i follow closely like $CCCC $ALT $SLS … 🤫 Trying to figure out the right @BiotechBonesaw name… and whether discord is the right server and initial price point. Any thoughts from my fellow Tonixphiles? Tonmya is on its way. 🚀
1 · Reply
josegodoy
josegodoy May. 23 at 12:40 PM
$CCCC as the bulls and bears battle it out… - chart: simple line WEEKLY Bears: highlighted in red Bulls: highlighted in green Bulls take it (for now) Looking for a test of both* of the red lines that extend beyond the apex of the “triangle/wedge” *doesn’t have to happen but… $4+ on deck on our way to $6 An opinion
0 · Reply
vu_jade
vu_jade May. 22 at 9:03 PM
$CCCC resetting
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR May. 22 at 1:52 PM
$CCCC c4 to your door no beef no more
0 · Reply
TheUnmaker
TheUnmaker May. 22 at 1:15 PM
$TNXP overnight fake out shakeout before rip.. The force is strong with this one! $CCCC $SLS $RNAZ
0 · Reply
TheUnmaker
TheUnmaker May. 22 at 12:00 AM
$CCCC
0 · Reply
open_outcry
open_outcry May. 21 at 11:13 PM
$CCCC curious to watch 13D/G filings over the coming weeks. Squadron picked up a cool 5.5M shares on may 12th, the day before the spike to $3.92. there could be more institutional accumulation ongoing right now, but we'll only find out after the fact.
3 · Reply
2tacos_plis
2tacos_plis May. 21 at 8:15 PM
$CCCC Well,Well,Well!
0 · Reply
zawojak
zawojak May. 21 at 7:59 PM
$CCCC something is cooking 🍳
1 · Reply
vu_jade
vu_jade May. 21 at 6:55 PM
$CCCC nice
0 · Reply
Latest News on CCCC
C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026, 7:00 AM EDT - 4 days ago

C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026, 4:01 PM EDT - 5 days ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

2026-05-12T12:40:38.000Z - 12 days ago

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026, 7:00 AM EDT - 12 days ago

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 12 days ago

C4 Therapeutics Quarterly report: Q1 2026

C4 Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 12 days ago

C4 Therapeutics Earnings release: Q1 2026

C4 Therapeutics Slides: Investor presentation

May 12, 2026, 7:00 AM EDT - 12 days ago

C4 Therapeutics Slides: Investor presentation

C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 25 days ago

C4 Therapeutics Proxy statement: Proxy filing

C4 Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 25 days ago

C4 Therapeutics Proxy statement: Proxy filing

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

Apr 9, 2026, 9:34 AM EDT - 6 weeks ago

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics expands long-term partnership with Roche

2026-04-09T11:07:07.000Z - 6 weeks ago

C4 Therapeutics expands long-term partnership with Roche

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Apr 9, 2026, 6:59 AM EDT - 6 weeks ago

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 6 weeks ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics doses first patient in cemsidomide trial

2026-03-25T11:25:28.000Z - 2 months ago

C4 Therapeutics doses first patient in cemsidomide trial

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 25, 2026, 7:00 AM EDT - 2 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 2 months ago

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 2 months ago

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

C4 Therapeutics Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 2 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics price target raised to $7 from $5 at Barclays

2026-02-27T10:25:32.000Z - 3 months ago

C4 Therapeutics price target raised to $7 from $5 at Barclays

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

2026-02-26T12:08:51.000Z - 3 months ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Annual report: Q4 2025

C4 Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Earnings release: Q4 2025

C4 Therapeutics Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Slides: Corporate presentation

C4 Therapeutics price target raised to $30 from $20 at Brookline

2026-02-23T17:07:13.000Z - 3 months ago

C4 Therapeutics price target raised to $30 from $20 at Brookline

C4 Therapeutics to Participate in Upcoming March Conferences

Feb 23, 2026, 7:10 AM EST - 3 months ago

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

2026-02-23T12:06:05.000Z - 3 months ago

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 23, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 11:30 AM EST - 3 months ago

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics outlines milestones through 2028

2026-01-14T12:05:59.000Z - 4 months ago

C4 Therapeutics outlines milestones through 2028

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Jan 14, 2026, 7:00 AM EST - 4 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics price target lowered to $5 from $10 at Barclays

2025-12-17T10:55:09.000Z - 5 months ago

C4 Therapeutics price target lowered to $5 from $10 at Barclays

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 6 months ago

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

C4 Therapeutics initiated with a Buy at TD Cowen

2025-12-02T10:40:12.000Z - 6 months ago

C4 Therapeutics initiated with a Buy at TD Cowen

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

C4 Therapeutics files $400M mixed securities shelf

2025-11-21T21:10:22.000Z - 6 months ago

C4 Therapeutics files $400M mixed securities shelf

C4 Therapeutics Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 8:30 AM EST - 6 months ago

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

2025-11-06T12:24:51.000Z - 7 months ago

C4 Therapeutics reports Q3 EPS (44c), consensus (38c)

C4 Therapeutics sees cash runway to the end of 2028

2025-11-06T12:24:45.000Z - 7 months ago

C4 Therapeutics sees cash runway to the end of 2028

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 7 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

C4 Therapeutics Earnings release: Q3 2025

C4 Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

C4 Therapeutics Quarterly report: Q3 2025

C4 Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 6:00 PM EST - 7 months ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 7 months ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics prices $125M underwritten offering

2025-10-16T11:20:33.000Z - 7 months ago

C4 Therapeutics prices $125M underwritten offering

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Oct 16, 2025, 7:08 AM EDT - 7 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics announces trial collab, supply agreement with Pfizer

2025-10-01T11:10:58.000Z - 8 months ago

C4 Therapeutics announces trial collab, supply agreement with Pfizer

PFE

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Oct 1, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

2025-09-23T10:15:16.000Z - 8 months ago

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

C4 Therapeutics price target raised to $10 from $8 at Barclays

2025-09-22T11:15:14.000Z - 8 months ago

C4 Therapeutics price target raised to $10 from $8 at Barclays

C4 Therapeutics presents data from Phase 1 trial of cemsidomide

2025-09-21T14:55:14.000Z - 8 months ago

C4 Therapeutics presents data from Phase 1 trial of cemsidomide

C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 3:00 PM EDT - 8 months ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Slides: Status Update

Sep 20, 2025, 3:00 PM EDT - 8 months ago

C4 Therapeutics Slides: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 20, 2025, 11:00 AM EDT - 8 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics initiated with an Overweight at Barclays

2025-09-16T20:50:38.000Z - 8 months ago

C4 Therapeutics initiated with an Overweight at Barclays

C4 Therapeutics initiated with an Overweight at Barclays

2025-09-16T20:21:58.000Z - 8 months ago

C4 Therapeutics initiated with an Overweight at Barclays

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 4, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Sep 3, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 10 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

C4 Therapeutics Earnings release: Q2 2025

C4 Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

C4 Therapeutics Quarterly report: Q2 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q1 2025

C4 Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q1 2025

C4 Therapeutics Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Earnings release: Q4 2024

C4 Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Annual report: Q4 2024

C4 Therapeutics Slides: Corporate Presentation

Feb 26, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

C4 Therapeutics Slides: FY 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Slides: FY 2025

C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Slides: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Slides: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Registration statement: Registration Filing

Oct 31, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Registration statement: Registration Filing

C4 Therapeutics Quarterly report: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q3 2024

C4 Therapeutics Earnings release: Q3 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q3 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 8:35 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Press release: Study Update

C4 Therapeutics Slides: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Slides: Study Update

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Quarterly report: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 1 year ago

C4 Therapeutics Quarterly report: Q2 2024

C4 Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:04 AM EDT - 1 year ago

C4 Therapeutics Earnings release: Q2 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 2 years ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jul 15, 2024, 12:00 PM EDT - 2 years ago

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q1 2024

C4 Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q1 2024

C4 Therapeutics Slides: Corporate Presentation

May 7, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Proxy statement: Proxy Filing

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 16, 2024, 10:30 AM EDT - 2 years ago

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Earnings release: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Earnings release: Q4 2023

C4 Therapeutics Annual report: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Annual report: Q4 2023

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

C4 Therapeutics Slides: FY 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Slides: FY 2024

C4 Therapeutics Slides: Corporate Presentation

Jan 11, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Slides: Corporate Presentation

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics blasts off: what's next?

Dec 18, 2023, 8:58 AM EST - 2 years ago

C4 Therapeutics blasts off: what's next?

C4 Therapeutics Transcript: Study Update

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Quarterly report: Q3 2023

C4 Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

C4 Therapeutics Earnings release: Q3 2023

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

JuggernautRaider
JuggernautRaider May. 23 at 5:40 PM
$TNXP in touch with a former tonix employee right now gathering info… my private server will also feature competitive intelligence you won’t get anywhere on TNXP and other companies i follow closely like $CCCC $ALT $SLS … 🤫 Trying to figure out the right @BiotechBonesaw name… and whether discord is the right server and initial price point. Any thoughts from my fellow Tonixphiles? Tonmya is on its way. 🚀
1 · Reply
josegodoy
josegodoy May. 23 at 12:40 PM
$CCCC as the bulls and bears battle it out… - chart: simple line WEEKLY Bears: highlighted in red Bulls: highlighted in green Bulls take it (for now) Looking for a test of both* of the red lines that extend beyond the apex of the “triangle/wedge” *doesn’t have to happen but… $4+ on deck on our way to $6 An opinion
0 · Reply
vu_jade
vu_jade May. 22 at 9:03 PM
$CCCC resetting
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR May. 22 at 1:52 PM
$CCCC c4 to your door no beef no more
0 · Reply
TheUnmaker
TheUnmaker May. 22 at 1:15 PM
$TNXP overnight fake out shakeout before rip.. The force is strong with this one! $CCCC $SLS $RNAZ
0 · Reply
TheUnmaker
TheUnmaker May. 22 at 12:00 AM
$CCCC
0 · Reply
open_outcry
open_outcry May. 21 at 11:13 PM
$CCCC curious to watch 13D/G filings over the coming weeks. Squadron picked up a cool 5.5M shares on may 12th, the day before the spike to $3.92. there could be more institutional accumulation ongoing right now, but we'll only find out after the fact.
3 · Reply
2tacos_plis
2tacos_plis May. 21 at 8:15 PM
$CCCC Well,Well,Well!
0 · Reply
zawojak
zawojak May. 21 at 7:59 PM
$CCCC something is cooking 🍳
1 · Reply
vu_jade
vu_jade May. 21 at 6:55 PM
$CCCC nice
0 · Reply
josegodoy
josegodoy May. 21 at 6:34 PM
$CCCC berry, berry nice
0 · Reply
John_week
John_week May. 21 at 1:40 PM
$CCCC
0 · Reply
vu_jade
vu_jade May. 20 at 7:31 PM
$CCCC bouncing off support
0 · Reply
2tacos_plis
2tacos_plis May. 20 at 5:03 PM
$CCCC
0 · Reply
open_outcry
open_outcry May. 20 at 12:25 AM
$CCCC any catalysts on the horizon in the near term?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 19 at 11:42 PM
$CCCC RSI: 64.03, MACD: 0.1471 Vol: 0.29, MA20: 3.06, MA50: 2.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
zawojak
zawojak May. 19 at 11:18 PM
$CCCC a whole market down, not only "us". 😉
1 · Reply
John_week
John_week May. 19 at 7:24 PM
$CCCC what a po
0 · Reply
carrotcarrot
carrotcarrot May. 19 at 2:21 PM
$CCCC byebye cccc
1 · Reply
vu_jade
vu_jade May. 19 at 1:54 PM
$CCCC Another example of when you see that huge spike .. sell your whole position, no matter how bullish you are …
0 · Reply
aquira
aquira May. 18 at 6:45 PM
$CCCC fooken hell. Down again. All gainzzzz lost in 2 days
2 · Reply
open_outcry
open_outcry May. 18 at 5:13 PM
$CCCC moment of truth
0 · Reply